Evidence map›Paper›PMID 42251673›Full record

ReviewAngewandte Chemie (International ed. in English)2026

Advances in BODIPY Derivatives for Antibacterial Phototherapy.

Li Lv, Heejeong Kim, Hongchen Zhai, Hanqi Ren, Silu Wang, Cong Sun, Yafu Wang, Hosoowi Lee, Juyoung Yoon, Hua Zhang

Abstract readReview
In one paragraph

Review in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Li LvSchool of Chemistry and Chemical Engineering, Henan International Joint Laboratory of Smart Molecules and Identification and Diagnostic Functions, Henan Normal University, Xinxiang, Henan, P. R. China.
Heejeong KimDepartment of Chemistry and Nanoscience, Ewha Womans University, Seoul, South Korea.
Hongchen ZhaiSchool of Chemistry and Chemical Engineering, Henan International Joint Laboratory of Smart Molecules and Identification and Diagnostic Functions, Henan Normal University, Xinxiang, Henan, P. R. China.
Hanqi RenSchool of Chemistry and Chemical Engineering, Henan International Joint Laboratory of Smart Molecules and Identification and Diagnostic Functions, Henan Normal University, Xinxiang, Henan, P. R. China.
Silu WangSchool of Chemistry and Chemical Engineering, Henan International Joint Laboratory of Smart Molecules and Identification and Diagnostic Functions, Henan Normal University, Xinxiang, Henan, P. R. China.
Cong SunSchool of Chemistry and Chemical Engineering, Henan International Joint Laboratory of Smart Molecules and Identification and Diagnostic Functions, Henan Normal University, Xinxiang, Henan, P. R. China.
Yafu WangSchool of Chemistry and Chemical Engineering, Henan International Joint Laboratory of Smart Molecules and Identification and Diagnostic Functions, Henan Normal University, Xinxiang, Henan, P. R. China.
Hosoowi LeeDepartment of Chemistry and Nanoscience, Ewha Womans University, Seoul, South Korea.ORCID 0000-0003-3896-1926
Juyoung YoonDepartment of Chemistry and Nanoscience, Ewha Womans University, Seoul, South Korea.ORCID 0000-0002-1728-3970
Hua ZhangSchool of Chemistry and Chemical Engineering, Henan International Joint Laboratory of Smart Molecules and Identification and Diagnostic Functions, Henan Normal University, Xinxiang, Henan, P. R. China.ORCID 0000-0002-7593-4946

Funding

National Natural Science Foundation of China 22408090National Natural Science Foundation of China 22574041National Natural Science Foundation of China U25A20619National Research Foundation of Korea 2022R1A2C3005420National Research Foundation of Korea RS-2024-00345550Natural Science Foundation of Henan 2252300421079
6 · The paper itself

Abstract

The escalating threat posed by antibiotic-resistant bacteria and biofilm-associated infections has driven increasing interest in non-antibiotic antibacterial strategies. Antibacterial phototherapy (PT), including photodynamic therapy (PDT) and photothermal therapy (PTT), has attracted considerable attention owing to its spatiotemporal controllability, broad-spectrum antibacterial activity, and low propensity for inducing drug resistance. Boron-dipyrromethene (BODIPY) dyes, featuring exceptional structural tunability and favorable photophysical properties, have emerged as versatile scaffolds for the construction of antibacterial phototherapeutic systems. Through molecular engineering strategies including cationization, heavy-atom incorporation, and π-conjugation extension, combined with nanoassembly approaches, both the excited-state processes of BODIPY and its interactions with bacterial interfaces can be precisely regulated. Integration into diverse nanoplatforms further improves aqueous dispersibility, biological stability, and accumulation at bacterial or biofilm interfaces, thereby enhancing reactive oxygen species (ROS) generation or enabling photothermal effects to achieve PDT, PTT, or synergistic antibacterial therapy. This review systematically summarizes the design strategies and structure-activity relationships of BODIPY-based antibacterial phototherapy reported over the past five years, covering molecular engineering of small-molecule photosensitizers and nanoplatforms, bacterial targeting and carrier design, and discussing the challenges and future perspectives associated with clinical translation, particularly in terms of biosafety and targeted delivery.

Indexed as

Anti-Bacterial AgentsBoron CompoundsPhotosensitizing AgentsPhototherapyHumansPhotochemotherapyStructure-Activity Relationship4,4-difluoro-4-bora-3a,4a-diaza-s-indaceneAnti-Bacterial AgentsBoron CompoundsPhotosensitizing Agentsantibacterial phototherapyBODIPYmultidrug‐resistant bacteriaphotodynamic therapyphotothermal therapy

Identifiers

PMID42251673
PMCPMC13383192

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.